- Home
- SANA vs AURA Comparison
SANA vs AURA Comparison
Compare SANA & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SANA | AURA |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.1M | 713.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SANA | AURA |
|---|---|---|
| Price | $4.14 | $7.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.80 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 3.9M | 689.2K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.24 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.61 | $4.73 |
| 52 Week High | $6.55 | $9.54 |
Technical Indicators
Market Signals| Indicator | SANA | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 77.68 | 53.59 |
| Support Level | $3.93 | $6.89 |
| Resistance Level | $4.42 | $7.81 |
| Average True Range (ATR) | 0.26 | 0.54 |
| MACD | 0.12 | 0.09 |
| Stochastic Oscillator | 99.64 | 61.40 |
Price Performance
Historical ComparisonAbout SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.